Developing game changing treatments and cell therapies for severe diseases

We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.

MORE ABOUT US

“We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating diseases.”

Professor Ann Logan,
Scientific Director, Neuregenix Ltd.

NEWS

4 March 2019
TFS International AB (TFS) appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Viken – 4th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
8 February 2019
TIKOMED successfully closed fundraising of 8 Million Euros
Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its…
Read More
6 February 2019
Shadow Lake Group appointed Strategic Advisor and Business Development representative for the licensing process of IBsolvMIR® in Canada
Viken – 6th February 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
30 November 2018
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
VIKEN, Sweden, November 19, 2018 (Newswire) -TIKOMED, a specialty pharmaceutical company developing IBsolvMIR, an infusion…
Read More

EVENTS

Cell and Gene on the Med
Date: 23 April 2019 - 25 April 2019
Venue: Hotel Arts Barcelona Marina 19-21 08005 Barcelona, Spain
Read More
BIO International
Date: 3 June 2019 - 6 March 2019
Venue: Pennsylvania Convention Center: 1101 Arch St, Philadelphia, PA
Read More
MORE NEWS & EVENTS

SUBSCRIBE